Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Previous reports suggest benefit of neoadjuvant chemotherapy/chemoradiation treatment for
borderline resectable cholangiocarcinoma. This study is a single center prospective phase II
study of neoadjuvant chemotherapy with mFOLFOXIRI in patients with borderline resectable
cholangiocarcinoma.